(IGMS) IGM Biosciences - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4495851085
IGMS: IgM Antibodies, Cancer Treatments, Autoimmune Disease Treatments
IGM Biosciences, Inc. (NASDAQ: IGMS) is a clinical-stage biotechnology company pioneering the development of Immunoglobulin M (IgM) antibodies, leveraging their unique pentameric structure for enhanced binding and efficacy. The company focuses on treating cancer and autoimmune diseases, capitalizing on IgMs potential for stronger interactions compared to traditional IgG antibodies.
Their pipeline includes Aplitabart, a Death Receptor 5 Agonist IgM antibody targeting colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody in Phase Ib trials for myositis, systemic lupus erythematosus, and rheumatoid arthritis; and IGM-2644, a bispecific T cell engager targeting CD38 and CD3 for autoimmune diseases. Collaborating with Genzyme Corporation, IGM Biosciences aims to advance IgM antibody technology across various therapeutic areas.
Originally named Palingen, Inc., the company rebranded as IGM Biosciences in 2010, reflecting its focus on innovative antibody therapies. Headquartered in Mountain View, California, IGM Biosciences continues to explore the potential of IgM antibodies in addressing unmet medical needs.
Over the next three months, IGM Biosciences stock (NASDAQ: IGMS) is expected to experience volatility influenced by its current technical and fundamental indicators. Trading at $1.35 with a 20-day average volume of 254,007, the stock is below its 20 and 50-day SMAs, suggesting bearish momentum. The 200-day SMA of $8.97 indicates a significant decline, while an ATR of 0.30 signals moderate price fluctuations.
Fundamentally, with a market cap of $79.09M and a P/B ratio of 0.95, the stock is near its book value, reflecting the clinical-stage nature of the company. The P/S ratio of 27.10 highlights a premium on sales potential. Given the lack of profitability (P/E: 0.00), investor sentiment may hinge on clinical trial outcomes and partnership developments.
Technically, the stock may face resistance at the 20-day SMA ($1.39) and 50-day SMA ($2.81). Support levels may emerge near recent lows, influenced by the ATR. The 200-day SMA suggests a potential long-term downtrend. Investors should monitor for potential breakouts or further declines, considering the moderate volatility indicated by the ATR.
Additional Sources for IGMS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
IGMS Stock Overview
| Market Cap in USD | 77m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC Sub-Industry | Biotechnology |
| IPO / Inception | 2019-09-18 |
IGMS Stock Ratings
| Growth 5y | -82.5% |
| Fundamental | - |
| Dividend | 0.0% |
| Rel. Strength Industry | -86.9 |
| Analysts | 2.91/5 |
| Fair Price Momentum | 0.74 USD |
| Fair Price DCF | - |
IGMS Dividends
No Dividends PaidIGMS Growth Ratios
| Growth Correlation 3m | -95% |
| Growth Correlation 12m | -32.2% |
| Growth Correlation 5y | -87.1% |
| CAGR 5y | -47.63% |
| CAGR/Max DD 5y | -0.48 |
| Sharpe Ratio 12m | -2.02 |
| Alpha | -113.01 |
| Beta | 3.22 |
| Volatility | 97.52% |
| Current Volume | 274.2k |
| Average Volume 20d | 224.6k |
As of March 15, 2025, the stock is trading at USD 1.24 with a total of 274,190 shares traded.
Over the past week, the price has changed by -6.44%, over one month by -13.64%, over three months by -83.31% and over the past year by -87.89%.
No, based on ValueRay Analyses, IGM Biosciences (NASDAQ:IGMS) is currently (March 2025) a stock to sell. It has a ValueRay Growth Rating of -82.50 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IGMS as of March 2025 is 0.74. This means that IGMS is currently overvalued and has a potential downside of -40.32%.
IGM Biosciences has received a consensus analysts rating of 2.91. Therefor, it is recommend to hold IGMS.
- Strong Buy: 1
- Buy: 0
- Hold: 8
- Sell: 1
- Strong Sell: 1
According to ValueRays Forecast Model, IGMS IGM Biosciences will be worth about 0.9 in March 2026. The stock is currently trading at 1.24. This means that the stock has a potential downside of -31.45%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 3 | 144.4% |
| Analysts Target Price | 11.4 | 822.6% |
| ValueRay Target Price | 0.9 | -31.5% |